Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer
Annals of Surgical Treatment and Research
;
: 161-167, 2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-716855
ABSTRACT
PURPOSE:
This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer.METHODS:
This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume).RESULTS:
All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis.CONCLUSION:
Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Rate
/
Splénomégalie
/
Leucovorine
/
Analyse multifactorielle
/
Études rétrospectives
/
Côlon
/
Tumeurs du côlon
/
Traitement médicamenteux
/
Fluorouracil
/
Panax
Type d'étude:
Étude observationnelle
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Annals of Surgical Treatment and Research
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS